The European Union’s drug regulator on Oct. 1 recommended updating the label for Johnson & Johnson’s COVID-19 vaccine with warnings for two more serious health conditions likely linked with the vaccine. The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that the use of the J&J vaccine is possibly linked with vein clotting and an immune condition that causes the immune system to attack blood platelets. “The PRAC has concluded that there is a possible link to rare cases of venous thromboembolism (VTE) with COVID-19 Vaccine Janssen,” the committee meeting highlights stated. Venous thromboembolism “is a condition in which a blood clot forms in a deep vein, usually in a leg, arm, or groin, and may travel to the lungs causing a blockage of the blood supply, with possible life-threatening consequences,” the committee said. Janssen, a J&J company, did not respond to a request for comment. COVID-19 is the disease caused by …